Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TFC-837
- Development stage
- Preclinical
- Lead developer
- Sirona Biochem
01
Overview
**TFC-837** is a synthetic and stabilized antifreeze glycoprotein developed by Sirona Biochem for anti-aging and regenerative medicine applications. It protects human fibroblast cells from stressed conditions, including serum deprivation (75% cell survival after 12 days vs. 0% unprotected), UV irradiation, and oxidative stress, by mimicking natural antifreeze glycoproteins to prevent cellular damage.[1][4][13][16] Potential therapeutic uses extend beyond cosmetics to pharmaceutical applications such as extending blood platelet storage, improving cell transplant outcomes, enhancing stem-cell storage, and supporting organ transplantation by mitigating reperfusion injury and stress responses.[1][16]
- Other names
- anti-aging glycoprotein TFC-837antifreeze glycoprotein TFC-837
Beyond the preview
Go deeper on TFC-837.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TFC-837.